AGEP |
Acute Generalized Exanthematous Pustulosis |
BRAFi |
BRAF-inhibitors |
BSA |
Body Surface Area |
CTLA-4 |
T lymphocyte-associated antigen-4 |
DRESS |
Drug Reaction with Eosinophilia and Systemic Symptoms |
EGFR |
Epidermal Growth Factor Receptor Inhibitors |
ICIs |
Immune Checkpoint-Inhibitors |
IGF-1 |
Insulin-like Growing Factor-1 |
irAE |
Immune-related Adverse Event |
MAPK |
Mitogen-activated Protein Kinase |
MEKi |
MEK-inhibitors |
NMSC |
Nonmelanoma Skin Cancer |
PD-1 |
Programmed Cell Death Protein 1 |
PD-L1 |
Programmed Death Ligand 1 |
PTCH1 |
Patched Homologue 1 |
SCC |
Squamous Cell Carcinomas |
SMO |
Smoothened Homologue |